Evidence map›Paper›PMID 40740763›Full record

ArticleFrontiers in immunology2025

Immune microenvironment heterogeneity characterizes biologically distinct KRAS

Jing Zeng, Qingli Li, Kemin Li, Lu Yang, Lian Xu, Wei Wang, Kaixuan Yang, Qingbo Wei, Jin Wang, Changbin Zhu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jing ZengDepartment of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Qingli LiDepartment of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Kemin LiDepartment of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Lu YangDepartment of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.
Lian XuKey Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China.
Wei WangKey Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China.
Kaixuan YangKey Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China.
Qingbo WeiDepartment of Translational Medicine, Amoy Diagnostics Co., Ltd, Fujian, Xiamen, China.
Jin WangDepartment of Translational Medicine, Amoy Diagnostics Co., Ltd, Fujian, Xiamen, China.
Changbin ZhuDepartment of Translational Medicine, Amoy Diagnostics Co., Ltd, Fujian, Xiamen, China.
Rutie YinDepartment of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to uncover the molecular biology and immune microenvironment of gynecological mesonephric-like adenocarcinoma (MLA). Methods: To determine the comprehensive characteristics of MLA, 17 patients with MLA were retrospectively enrolled in this study. Whole-exome sequencing and mRNA sequencing were performed to explore the molecular features. The biological differences between MLAs and epithelial-initiated gynecologic tumors reported in The Cancer Genome Atlas database were also analyzed. Results: Conclusion: This is the first study to demonstrate the comprehensive molecular characteristics of MLA and detect biologically distinct subtypes of

Indexed as

AdenocarcinomaClass I Phosphatidylinositol 3-KinasesMutationProto-Oncogene Proteins p21(ras)Tumor MicroenvironmentAdultAgedExome SequencingFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedRetrospective StudiesTranscriptomeClass I Phosphatidylinositol 3-KinasesKRAS protein, humanPIK3CA protein, humanProto-Oncogene Proteins p21(ras)immune microenvironmentkidney developmentKRASmesonephric-like adenocarcinomamolecular biologytranscriptomic profiling gynecological mesonephric-like adenocarcinomatumor microenvironmentwhole-exome

Identifiers

PMID40740763
PMCPMC12307467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.